Clinical effectiveness of statin therapy after ischemic stroke: Primary results from the statin therapeutic area of the patient-centered research into outcomes stroke patients prefer and effectiveness research (PROSPER) study

Emily C. O'Brien, Melissa A. Greiner, Ying Xian, Gregg C. Fonarow, DaiWai M. Olson, Lee H. Schwamm, Deepak L. Bhatt, Eric E. Smith, Lesley Maisch, Deidre Hannah, Brianna Lindholm, Eric D. Peterson, Michael J. Pencina, Adrian F. Hernandez

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background - In patients with ischemic stroke, data on the real-world effectiveness of statin therapy for clinical and patient-centered outcomes are needed to better inform shared decision making. Methods and Results - Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) is a Patient-Centered Outcomes Research Institute-funded research program designed with stroke survivors to evaluate the effectiveness of poststroke therapies. We linked data on patients ≥65 years of age enrolled in the Get With The Guidelines-Stroke Registry to Medicare claims. Two-year to postdischarge outcomes of those discharged on a statin versus not on a statin were adjusted through inverse probability weighting. Our coprimary outcomes were major adverse cardiovascular events and home time (days alive and out of a hospital or skilled nursing facility). Secondary outcomes included all-cause mortality, all-cause readmission, cardiovascular readmission, and hemorrhagic stroke. From 2007 to 2011, 77 468 patients who were not taking statins at the time of admission were hospitalized with ischemic stroke; of these, 71% were discharged on statin therapy. After adjustment, statin therapy at discharge was associated with a lower hazard of major adverse cardiovascular events (hazard ratio, 0.91; 95% confidence interval, 0.87-0.94), 28 more home-time days after discharge (P

Original languageEnglish (US)
Pages (from-to)1404-1413
Number of pages10
JournalCirculation
Volume132
Issue number15
DOIs
StatePublished - Oct 13 2015

Fingerprint

Patient Outcome Assessment
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Stroke
Research
Therapeutics
Skilled Nursing Facilities
Social Adjustment
Medicare
Survivors
Registries
Decision Making
Guidelines
Confidence Intervals
Mortality

Keywords

  • hydroxymethylglutaryl-CoA reductase inhibitors
  • lipids
  • patient-centered outcomes research
  • stroke

ASJC Scopus subject areas

  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Clinical effectiveness of statin therapy after ischemic stroke : Primary results from the statin therapeutic area of the patient-centered research into outcomes stroke patients prefer and effectiveness research (PROSPER) study. / O'Brien, Emily C.; Greiner, Melissa A.; Xian, Ying; Fonarow, Gregg C.; Olson, DaiWai M.; Schwamm, Lee H.; Bhatt, Deepak L.; Smith, Eric E.; Maisch, Lesley; Hannah, Deidre; Lindholm, Brianna; Peterson, Eric D.; Pencina, Michael J.; Hernandez, Adrian F.

In: Circulation, Vol. 132, No. 15, 13.10.2015, p. 1404-1413.

Research output: Contribution to journalArticle

O'Brien, EC, Greiner, MA, Xian, Y, Fonarow, GC, Olson, DM, Schwamm, LH, Bhatt, DL, Smith, EE, Maisch, L, Hannah, D, Lindholm, B, Peterson, ED, Pencina, MJ & Hernandez, AF 2015, 'Clinical effectiveness of statin therapy after ischemic stroke: Primary results from the statin therapeutic area of the patient-centered research into outcomes stroke patients prefer and effectiveness research (PROSPER) study', Circulation, vol. 132, no. 15, pp. 1404-1413. https://doi.org/10.1161/CIRCULATIONAHA.115.016183
O'Brien, Emily C. ; Greiner, Melissa A. ; Xian, Ying ; Fonarow, Gregg C. ; Olson, DaiWai M. ; Schwamm, Lee H. ; Bhatt, Deepak L. ; Smith, Eric E. ; Maisch, Lesley ; Hannah, Deidre ; Lindholm, Brianna ; Peterson, Eric D. ; Pencina, Michael J. ; Hernandez, Adrian F. / Clinical effectiveness of statin therapy after ischemic stroke : Primary results from the statin therapeutic area of the patient-centered research into outcomes stroke patients prefer and effectiveness research (PROSPER) study. In: Circulation. 2015 ; Vol. 132, No. 15. pp. 1404-1413.
@article{056a29e1c941469caa161f84805d66fd,
title = "Clinical effectiveness of statin therapy after ischemic stroke: Primary results from the statin therapeutic area of the patient-centered research into outcomes stroke patients prefer and effectiveness research (PROSPER) study",
abstract = "Background - In patients with ischemic stroke, data on the real-world effectiveness of statin therapy for clinical and patient-centered outcomes are needed to better inform shared decision making. Methods and Results - Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) is a Patient-Centered Outcomes Research Institute-funded research program designed with stroke survivors to evaluate the effectiveness of poststroke therapies. We linked data on patients ≥65 years of age enrolled in the Get With The Guidelines-Stroke Registry to Medicare claims. Two-year to postdischarge outcomes of those discharged on a statin versus not on a statin were adjusted through inverse probability weighting. Our coprimary outcomes were major adverse cardiovascular events and home time (days alive and out of a hospital or skilled nursing facility). Secondary outcomes included all-cause mortality, all-cause readmission, cardiovascular readmission, and hemorrhagic stroke. From 2007 to 2011, 77 468 patients who were not taking statins at the time of admission were hospitalized with ischemic stroke; of these, 71{\%} were discharged on statin therapy. After adjustment, statin therapy at discharge was associated with a lower hazard of major adverse cardiovascular events (hazard ratio, 0.91; 95{\%} confidence interval, 0.87-0.94), 28 more home-time days after discharge (P",
keywords = "hydroxymethylglutaryl-CoA reductase inhibitors, lipids, patient-centered outcomes research, stroke",
author = "O'Brien, {Emily C.} and Greiner, {Melissa A.} and Ying Xian and Fonarow, {Gregg C.} and Olson, {DaiWai M.} and Schwamm, {Lee H.} and Bhatt, {Deepak L.} and Smith, {Eric E.} and Lesley Maisch and Deidre Hannah and Brianna Lindholm and Peterson, {Eric D.} and Pencina, {Michael J.} and Hernandez, {Adrian F.}",
year = "2015",
month = "10",
day = "13",
doi = "10.1161/CIRCULATIONAHA.115.016183",
language = "English (US)",
volume = "132",
pages = "1404--1413",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "15",

}

TY - JOUR

T1 - Clinical effectiveness of statin therapy after ischemic stroke

T2 - Primary results from the statin therapeutic area of the patient-centered research into outcomes stroke patients prefer and effectiveness research (PROSPER) study

AU - O'Brien, Emily C.

AU - Greiner, Melissa A.

AU - Xian, Ying

AU - Fonarow, Gregg C.

AU - Olson, DaiWai M.

AU - Schwamm, Lee H.

AU - Bhatt, Deepak L.

AU - Smith, Eric E.

AU - Maisch, Lesley

AU - Hannah, Deidre

AU - Lindholm, Brianna

AU - Peterson, Eric D.

AU - Pencina, Michael J.

AU - Hernandez, Adrian F.

PY - 2015/10/13

Y1 - 2015/10/13

N2 - Background - In patients with ischemic stroke, data on the real-world effectiveness of statin therapy for clinical and patient-centered outcomes are needed to better inform shared decision making. Methods and Results - Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) is a Patient-Centered Outcomes Research Institute-funded research program designed with stroke survivors to evaluate the effectiveness of poststroke therapies. We linked data on patients ≥65 years of age enrolled in the Get With The Guidelines-Stroke Registry to Medicare claims. Two-year to postdischarge outcomes of those discharged on a statin versus not on a statin were adjusted through inverse probability weighting. Our coprimary outcomes were major adverse cardiovascular events and home time (days alive and out of a hospital or skilled nursing facility). Secondary outcomes included all-cause mortality, all-cause readmission, cardiovascular readmission, and hemorrhagic stroke. From 2007 to 2011, 77 468 patients who were not taking statins at the time of admission were hospitalized with ischemic stroke; of these, 71% were discharged on statin therapy. After adjustment, statin therapy at discharge was associated with a lower hazard of major adverse cardiovascular events (hazard ratio, 0.91; 95% confidence interval, 0.87-0.94), 28 more home-time days after discharge (P

AB - Background - In patients with ischemic stroke, data on the real-world effectiveness of statin therapy for clinical and patient-centered outcomes are needed to better inform shared decision making. Methods and Results - Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) is a Patient-Centered Outcomes Research Institute-funded research program designed with stroke survivors to evaluate the effectiveness of poststroke therapies. We linked data on patients ≥65 years of age enrolled in the Get With The Guidelines-Stroke Registry to Medicare claims. Two-year to postdischarge outcomes of those discharged on a statin versus not on a statin were adjusted through inverse probability weighting. Our coprimary outcomes were major adverse cardiovascular events and home time (days alive and out of a hospital or skilled nursing facility). Secondary outcomes included all-cause mortality, all-cause readmission, cardiovascular readmission, and hemorrhagic stroke. From 2007 to 2011, 77 468 patients who were not taking statins at the time of admission were hospitalized with ischemic stroke; of these, 71% were discharged on statin therapy. After adjustment, statin therapy at discharge was associated with a lower hazard of major adverse cardiovascular events (hazard ratio, 0.91; 95% confidence interval, 0.87-0.94), 28 more home-time days after discharge (P

KW - hydroxymethylglutaryl-CoA reductase inhibitors

KW - lipids

KW - patient-centered outcomes research

KW - stroke

UR - http://www.scopus.com/inward/record.url?scp=84944145325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944145325&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.115.016183

DO - 10.1161/CIRCULATIONAHA.115.016183

M3 - Article

C2 - 26246175

AN - SCOPUS:84944145325

VL - 132

SP - 1404

EP - 1413

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 15

ER -